Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)
The disclosed methods pertain to diagnosing whether a non-ablative, gene therapy is needed for reducing AF fibrosis in a subject, and if so, methods of reducing AF fibrosis in a subject using gene therapy with a dominant negative TGF-β R2 cDNA expression vector. Kits and computer program products are also described, wherein the kits provide materials for diagnosing and treating AF fibrosis, and the computer program products include a computer readable medium having computer readable program code for monitoring the efficacy of therapeutic ablation of fibrosis in a subject using a gene therapy method.
1. A method of reducing AF fibrosis in a subject, comprising:
(a) providing an isolated therapeutic DNA comprising a dominant negative TGF-β R2 cDNA expression vector that encodes and expresses dominant negative TGF-β R2 mRNA and protein in vivo;
(b) administering the isolated therapeutic DNA to myocardial tissue of the subject;
(c) measuring a plurality of recorded atrial EGMs for a region of myocardial tissue after administration of the isolated therapeutic DNA; and
(d) continuing administration with the isolated therapeutic DNA based upon detecting an absence of one or more continued significant changes in EGM characteristics in the plurality of recorded EGMs with administration of the therapeutic DNA;
wherein the absence of one or more continued significant changes in EGM characteristics in the plurality of recorded EGMs is indicative of a reduction in percent fibrosis not being retained at the region of myocardial tissue following administration of the isolated therapeutic DNA.
2. The method of claim 1 , wherein step (c) comprises analyzing the plurality of recorded atrial EGMs using at least one analytical subroutine selected from the group consisting of dominant frequency analysis (DF), organizational index analysis (OI), fractional interval analysis (FI) and Shannon Entropy analysis (ShEn).
3. The method of claim 1 , wherein the subject is a patient in need of preventative treatment for stroke or congestive heart failure as a result of atrial fibrillation.
4. The method of claim 1 , wherein the myocardial tissue comprises PLA.
5. The method of claim 1 , wherein administering the isolated therapeutic DNA to myocardial tissue of the subject comprises injecting the isolated therapeutic DNA.
6. A method of claim 1 , further comprising assessing AF characteristics following administering the isolated therapeutic DNA.
7. The method of claim 6 , wherein the AF characteristics comprise at least one member selected from the group consisting of AF duration and AF episode inducibility.
8. A method of reducing AF fibrosis in a subject, comprising:
(a) providing an isolated therapeutic DNA comprising a dominant negative TGF-β R2 cDNA expression vector that encodes and expresses dominant negative TGF-β R2 mRNA and protein in vivo;
(b) administering the isolated therapeutic DNA to myocardial tissue of the subject; and
(c) measuring a plurality of recorded atrial EGMs for a region of the myocardial tissue before and after administration of the isolated therapeutic DNA to monitor the efficacy of the isolated therapeutic DNA.
9. The method of claim 8 , further comprising: (d)
ceasing therapy with the isolated therapeutic DNA based upon detecting a presence of one or more continued significant changes in EGM characteristics in the plurality of recorded EGMs with administration of the therapeutic DNA;
wherein the presence of one or more continued significant changes in EGM characteristics in the plurality of recorded EGMs is indicative of a reduction in percent AF fibrosis being retained at the region of myocardial tissue following administration of the isolated therapeutic DNA.
10. The method of claim 8 , further comprising measuring the AF characteristics of the myocardial tissue, wherein the AF characteristics comprises at least one member selected from the group consisting of AF duration and AF episode inducibility.